Nininger Medical
Private Company
Funding information not available
Overview
Nininger Medical is an early-stage, pre-revenue medical device startup focused on innovative solutions for structural heart failure. Founded in 2019, the company is developing patent-pending transcatheter heart valve technology, indicating a minimally invasive therapeutic approach. Its initial development has been funded by an SBIR grant from the National Science Foundation, awarded in December 2020. The company operates in the large and growing structural heart disease market but remains in a pre-clinical or early R&D stage with no disclosed pipeline programs or leadership team.
Technology Platform
Patent-pending technology for transcatheter heart valve therapies, focused on minimally invasive treatment of structural heart failure. Specific mechanism undisclosed.
Opportunities
Risk Factors
Competitive Landscape
The transcatheter heart valve market is highly competitive, dominated by large players like Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific. These companies have extensive R&D budgets, commercial networks, and established clinical data, creating a high barrier to entry for a small startup like Nininger Medical.